TRACON Pharmaceuticals (NASDAQ:TCON) and Big Cypress Acquisition (OTCMKTS:BCYP) Head to Head Analysis

TRACON Pharmaceuticals (NASDAQ:TCON) and Big Cypress Acquisition (OTCMKTS:BCYP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Institutional and Insider Ownership

11.6% of TRACON Pharmaceuticals shares are held by institutional investors. Comparatively, 60.2% of Big Cypress Acquisition shares are held by institutional investors. 5.3% of TRACON Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares TRACON Pharmaceuticals and Big Cypress Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TRACON Pharmaceuticals	N/A	-237.65%	57.29%
Big Cypress Acquisition	N/A	N/A	N/A

Valuation and Earnings

This table compares TRACON Pharmaceuticals and Big Cypress Acquisition”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TRACON Pharmaceuticals	$12.05 million	0.01	-$3.59 million	$3.73	0.01
Big Cypress Acquisition	N/A	N/A	-$10,000.00	N/A	N/A

Big Cypress Acquisition has lower revenue, but higher earnings than TRACON Pharmaceuticals.

Analyst Recommendations

This is a summary of current recommendations and price targets for TRACON Pharmaceuticals and Big Cypress Acquisition, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TRACON Pharmaceuticals	0	1	0	0	2.00
Big Cypress Acquisition	0	0	0	0	0.00

TRACON Pharmaceuticals currently has a consensus price target of $60.00, indicating a potential upside of 171,328.57%. Given TRACON Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe TRACON Pharmaceuticals is more favorable than Big Cypress Acquisition.

Summary

TRACON Pharmaceuticals beats Big Cypress Acquisition on 5 of the 8 factors compared between the two stocks.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

About Big Cypress Acquisition

Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.